Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13216MR)

This product GTTS-WQ13216MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF9 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3604
UniProt ID Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13216MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12290MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ12301MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ1765MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ1599MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ15205MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ15158MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA T1h
GTTS-WQ11722MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ11151MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1333
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW